Lumakras

Amgen's request for full approval of Lumakras in lung cancer denied by FDA
Fierce Pharma
Wed, 12/27/23 - 11:02 pm
Amgen
Lumakras
FDA
non-small cell lung cancer
Merck's early KRAS data suggest combination-friendly safety
Fierce Biotech
Mon, 10/23/23 - 10:30 am
Merck
ESMO
KRAS inhibitors
Amgen
Lumakras
Amgen's Lumakras flunks FDA expert meeting, but market withdrawal looks unlikely for now
Fierce Pharma
Thu, 10/5/23 - 09:13 pm
Amgen
Lumakras
FDA
KRAS inhibitors
FDA Says ‘Systemic Bias’ in Amgen’s Lumakras Trial Ahead of Adcomm Meeting
BioSpace
Wed, 10/4/23 - 11:08 am
Amgen
Lumakras
non-small cell lung cancer
FDA
FDA staff says late-stage data 'not enough' for Amgen's lung cancer drug
Reuters
Tue, 10/3/23 - 10:23 am
Amgen
FDA
Lumakras
lung cancer
5 FDA decisions to watch in the fourth quarter
BioPharma Dive
Mon, 10/2/23 - 12:00 pm
FDA
Alnylam
Onpattro
ATTR amyloidosis
Vertex Pharmaceuticals
CRISPR Therapeutics
exa-cel
Bluebird Bio
Zynteglo
sickle cell disease
Bristol Myers Squibb
2seventy bio
Abecma
Multiple Myeloma
Amgen
Lumakras
non-small cell lung cancer
Pfizer
estrasimod
ulcerative colitis
KRAS crisis? FDA will gather advisers to weigh full approval for Amgen's Lumakras
Fierce Pharma
Mon, 08/21/23 - 06:56 pm
Amgen
Lumakras
KRAS inhibitors
FDA
Amgen Clinches Clinical Wins in SCLC and Colorectal Cancer
BioSpace
Fri, 08/4/23 - 12:30 pm
Amgen
oncology
colorectal cancer
small cell lung cancer
tarlatamab
Lumakras
Mirati's KRAS drug beats estimates in Q1, but Keytruda combo plan remains unclear
Fierce Pharma
Thu, 05/11/23 - 09:07 pm
Mirati Therapeutics
Krazati
Amgen
Lumakras
lung cancer
FDA Approval of Mirati Lung Cancer Drug Sets Stage for Competition With Amgen
MedCity News
Wed, 12/14/22 - 10:19 am
Amgen
Mirati Therapeutics
Krazati
Lumakras
FDA
lung cancer
Mirati is once again the subject of Big Pharma takeover talks: report
Fierce Biotech
Sun, 11/27/22 - 07:08 pm
Mirati Therapeutics
M&A
Amgen
Lumakras
Amgen’s Phase 3 win in lung cancer puts pressure on Mirati bid for speedy FDA nod
MedCity News
Wed, 08/31/22 - 10:23 am
Amgen
Lumakras
non-small cell lung cancer
clinical trials
World Lung – Toxicity scuppers Amgen’s first-line lung hopes
EP Vantage
Mon, 08/8/22 - 09:53 am
Amgen
World Lung
Lumakras
non-small cell lung cancer
Amgen's blockbuster hopeful Lumakras sees slower than expected sales in latest data, analyst says
Endpoints
Mon, 07/11/22 - 05:53 pm
Amgen
non-small cell lung cancer
Lumakras
ASCO: It's all tied up? Mirati's KRAS data are 'identical' to Amgen's, researcher says
Fierce Biotech
Mon, 06/6/22 - 10:33 am
ASCO 2022
Mirati Therapeutics
Amgen
Lumakras
adagrasib
lung cancer
Mirati matches Amgen with updated data for KRAS-blocking cancer drug
BioPharma Dive
Fri, 05/27/22 - 10:15 am
Mirati Therapeutics
Amgen
KRAS
adagrasib
Lumakras
clinical trials
Bristol's Abecma, Amgen's Lumakras headline record-setting oncology launch class as costs continue to balloon: IQVIA
Fierce Pharma
Thu, 05/26/22 - 10:53 pm
oncology
cancer
IQVIA
Bristol Myers Squibb
Abecma
Amgen
Lumakras
Novartis Highlights Early Data from Potential Lumakras Competitor at AACR
BioSpace
Tue, 04/12/22 - 10:49 am
Novartis
AACR
JDQ443
clinical trials
Amgen
Lumakras
AACR: 2 years in, Amgen fortifies Lumakras lung cancer data fortress for upcoming Mirati, Novartis KRAS battle
Fierce Pharma
Sun, 04/10/22 - 07:46 pm
AACR
Amgen
Lumakras
Mirati Therapeutics
Amgen Snags Another Approval for This Promising Cancer Drug
Motley Fool
Wed, 02/16/22 - 10:48 am
Amgen
Japan
Lumakras
non-small cell lung cancer
advanced non-small cell lung cancer

Pages